View in EDS PDF Full Text

Real-world efficacy and retention of guselkumab in psoriatic arthritis: insights from a 12-month multicenter study.

Saved in:
Bibliographic Details
Title: Real-world efficacy and retention of guselkumab in psoriatic arthritis: insights from a 12-month multicenter study.
Authors: Farina, N.1 farina.nicola@hsr.it, Boffini, N.1, Adinolfi, A.2, Batticciotto, A.3, Tomelleri, A.1, Cariddi, A.1, Calvisi, S.1, Baldissera, E.1, Matucci Cerinic, M.4, Cappelli, A.3, Epis, O.2, Dagna, L.1,4
Source: ARP Rheumatology. Jul-Sep2025, Vol. 4 Issue 3, p215-220. 6p.
Subjects: PSORIATIC arthritis, TREATMENT effectiveness, MEDICAL research, SEVERITY of illness index, SAFETY, PATIENT compliance, INFLAMMATION, BIOTHERAPY
Abstract: Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects joints, skin, and other structures. Guselkumab, an IL-23 inhibitor, has shown efficacy in clinical trials, but real-world data on its long-term use in PsA are limited. This study aimed to assess the efficacy, safety, and retention rate of guselkumab in a real-world cohort of PsA patients over 12 months. Methods: This retrospective study included PsA patients treated with guselkumab for at least 12 months across three medical centers. Patients were assessed at baseline and at 12 months using PsA disease activity scores. Retention rate at 12 months and reasons for discontinuation were recorded. Statistical analyses included descriptive statistics, Mann-Whitney tests for changes in disease activity, and Cox regression for identifying factors associated with treatment discontinuation. Results: We included 70 PsA patients. Significant reductions in disease activity were observed at 12 months for DAS28, DAPSA, MASES and ASDAS. The 12-month retention rate was 79%, with discontinuation primarily due to inefficacy. No significant adverse events were reported. Cox regression analysis found no significant associations between baseline characteristics and treatment discontinuation. Conclusions: Guselkumab demonstrated significant efficacy in reducing disease activity and a favorable retention rate over 12 months in a real-world PsA cohort. These findings support guselkumab as an effective treatment for PsA, although further prospective studies are needed to confirm long-term safety and efficacy. [ABSTRACT FROM AUTHOR]
Copyright of ARP Rheumatology is the property of Sociedade Portuguesa de Reumatologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 188791058
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-world efficacy and retention of guselkumab in psoriatic arthritis: insights from a 12-month multicenter study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Farina%2C+N%2E%22">Farina, N.</searchLink><relatesTo>1</relatesTo><i> farina.nicola@hsr.it</i><br /><searchLink fieldCode="AR" term="%22Boffini%2C+N%2E%22">Boffini, N.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Adinolfi%2C+A%2E%22">Adinolfi, A.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Batticciotto%2C+A%2E%22">Batticciotto, A.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Tomelleri%2C+A%2E%22">Tomelleri, A.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Cariddi%2C+A%2E%22">Cariddi, A.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Calvisi%2C+S%2E%22">Calvisi, S.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Baldissera%2C+E%2E%22">Baldissera, E.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Matucci+Cerinic%2C+M%2E%22">Matucci Cerinic, M.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Cappelli%2C+A%2E%22">Cappelli, A.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Epis%2C+O%2E%22">Epis, O.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Dagna%2C+L%2E%22">Dagna, L.</searchLink><relatesTo>1,4</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22ARP+Rheumatology%22">ARP Rheumatology</searchLink>. Jul-Sep2025, Vol. 4 Issue 3, p215-220. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22PSORIATIC+arthritis%22">PSORIATIC arthritis</searchLink><br /><searchLink fieldCode="DE" term="%22TREATMENT+effectiveness%22">TREATMENT effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22MEDICAL+research%22">MEDICAL research</searchLink><br /><searchLink fieldCode="DE" term="%22SEVERITY+of+illness+index%22">SEVERITY of illness index</searchLink><br /><searchLink fieldCode="DE" term="%22SAFETY%22">SAFETY</searchLink><br /><searchLink fieldCode="DE" term="%22PATIENT+compliance%22">PATIENT compliance</searchLink><br /><searchLink fieldCode="DE" term="%22INFLAMMATION%22">INFLAMMATION</searchLink><br /><searchLink fieldCode="DE" term="%22BIOTHERAPY%22">BIOTHERAPY</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects joints, skin, and other structures. Guselkumab, an IL-23 inhibitor, has shown efficacy in clinical trials, but real-world data on its long-term use in PsA are limited. This study aimed to assess the efficacy, safety, and retention rate of guselkumab in a real-world cohort of PsA patients over 12 months. Methods: This retrospective study included PsA patients treated with guselkumab for at least 12 months across three medical centers. Patients were assessed at baseline and at 12 months using PsA disease activity scores. Retention rate at 12 months and reasons for discontinuation were recorded. Statistical analyses included descriptive statistics, Mann-Whitney tests for changes in disease activity, and Cox regression for identifying factors associated with treatment discontinuation. Results: We included 70 PsA patients. Significant reductions in disease activity were observed at 12 months for DAS28, DAPSA, MASES and ASDAS. The 12-month retention rate was 79%, with discontinuation primarily due to inefficacy. No significant adverse events were reported. Cox regression analysis found no significant associations between baseline characteristics and treatment discontinuation. Conclusions: Guselkumab demonstrated significant efficacy in reducing disease activity and a favorable retention rate over 12 months in a real-world PsA cohort. These findings support guselkumab as an effective treatment for PsA, although further prospective studies are needed to confirm long-term safety and efficacy. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of ARP Rheumatology is the property of Sociedade Portuguesa de Reumatologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=188791058
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.63032/IEXQ7963
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 215
    Subjects:
      – SubjectFull: PSORIATIC arthritis
        Type: general
      – SubjectFull: TREATMENT effectiveness
        Type: general
      – SubjectFull: MEDICAL research
        Type: general
      – SubjectFull: SEVERITY of illness index
        Type: general
      – SubjectFull: SAFETY
        Type: general
      – SubjectFull: PATIENT compliance
        Type: general
      – SubjectFull: INFLAMMATION
        Type: general
      – SubjectFull: BIOTHERAPY
        Type: general
    Titles:
      – TitleFull: Real-world efficacy and retention of guselkumab in psoriatic arthritis: insights from a 12-month multicenter study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Farina, N.
      – PersonEntity:
          Name:
            NameFull: Boffini, N.
      – PersonEntity:
          Name:
            NameFull: Adinolfi, A.
      – PersonEntity:
          Name:
            NameFull: Batticciotto, A.
      – PersonEntity:
          Name:
            NameFull: Tomelleri, A.
      – PersonEntity:
          Name:
            NameFull: Cariddi, A.
      – PersonEntity:
          Name:
            NameFull: Calvisi, S.
      – PersonEntity:
          Name:
            NameFull: Baldissera, E.
      – PersonEntity:
          Name:
            NameFull: Matucci Cerinic, M.
      – PersonEntity:
          Name:
            NameFull: Cappelli, A.
      – PersonEntity:
          Name:
            NameFull: Epis, O.
      – PersonEntity:
          Name:
            NameFull: Dagna, L.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: Jul-Sep2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 27954552
          Numbering:
            – Type: volume
              Value: 4
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: ARP Rheumatology
              Type: main
ResultId 1